Agriculture And Food Tenders

Development Teams for the National Education Platform

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Miglustat, Atc A16ax06 for the Period September 1St, 2023 - August 31St, 2025

Conclusion of Non-Exclusive Discount Agreements According to §130A Paragraph 8 Sgb V for Various Active Ingredient(S)/Combinations with the Possibility of Conclusion at any Time as Part of the So-Called Open House Procedure

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Tofacitinib, Atc L04aa29 for the Period 09/01/2023 - 08/31/2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Natalizumab (Atc Code: L04ag03).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Ingredient Tafluprost Timolol, Atc S01ed51 for the Period 09/01/2023 - 08/31/2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Amifampridine, Atc N07xx05 for the Period September 1St, 2023 - August 31St, 2025

Conclusion of a Non-Exclusive Framework Contract for Test Engineering Services in the Open House Procedure of the Rhineland Branch, Published in 2023

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Lanreotide (Atc Code: H01cb03).

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Dabigatran, Atc B01ae07 for the Period September 1St, 2023 - August 31St, 2025